Research and Markets - Nitric Oxide Market: Expected to Rise to $96 billion in 2010 as New Drugs with Nitric Oxide based Mechanisms are introduced into the Market
Dublin--Research and Markets (researchandmarkets. com) has announced the addition of Nitric Oxide - Therapeutics, Markets and Companies to their offering.
(PRWEB) November 22, 2004
This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signalling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.
Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhalation for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
In the worldwide pharmaceutical market, share of drugs where NO is involved in the mechanism of action is over $30 billion. This share is projected to rise to $54.4 billion in 2005 and $96 billion in 2010 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
The number of companies that have a product or products involving NO and free radicals is quite large and difficult to determine precisely as this is not the main focus of these companies. The report includes profiles of 35 companies involved in this area of which 5 are exclusively devoted to NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Important collaborations in this area are tabulated.
Companies included in this report include:
AnorMED Inc, AstraZeneca, Aventis, Bayer, Beaufour Ipsen, Berlex Laboratories Inc, CALBIOCHEM, Cardion AG, Cayman Chemical Company, Cellegy Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Eukarion Inc, GlaxoSmithKline, Incara Pharmaceuticals Corporation, INO Therapeutics, Inotek Pharmaceuticals Corporation, MetaPhore Pharmaceuticals, MitoKor, NicOx SA, Ono Pharmaceutical Co Ltd, OXIS International Inc, OxoN Medica Inc, Pfizer, Prana Biotechnology, Limited, PulmoNOx Medical Inc, SensorMedics, Sigma Aldrich, Strakan Group plc, Strategic Science & Technologies Inc, Vasopharm Biotech GmbH
For more information visit http://www. researchandmarkets. com/reports/c9692 (http://www. researchandmarkets. com/reports/c9692)
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax : +353 1 4100 980
###
